Condition
Ulcerative colitis news across medications, symptoms, monitoring, procedures, research, access, and daily life.
Page 4 of 40 · 1912 articles
Cure8 could only read part of this source from benzinga.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis and Research and clinical trials.
The study suggests a dietary protein (ovotransferrin) can reduce colitis severity in mice by changing the gut microbiota and increasing certain secondary bile acids that lower inflammation and gut permeability.
New one-year trial analyses suggest mirikizumab (Omvoh) may help more people with moderate-to-severe ulcerative colitis or Crohn’s disease reach combined clinical and endoscopic goals and reduce steroid dependence.
These results suggest mirikizumab can achieve multiple treatment goals at once — symptoms, objective inflammation measures, and steroid-free status — outcomes that matter to people with IBD because they reflect both...
MMP-2 regulates tissue remodeling and inflammation in IBD; targeting it might help prevent barrier damage, chronic inflammation, or fibrosis but requires selective approaches to avoid harming normal repair processes.
The paper suggests a specific gut bacterium and its metabolite can protect against intestinal inflammation in mice by acting on enteric neurons, revealing a new neuro-immune pathway that could inform future IBD...
A phase 2 trial testing an oral integrin α4β7 inhibitor could matter because it explores a potential new mechanism for treating moderately to severely active ulcerative colitis, including patients who have failed other...
This registry-based study compares early control of inflammation on conventional therapy versus escalating to advanced treatments in newly diagnosed ulcerative colitis, using CRP and fecal calprotectin to define...
Microbiota-derived metabolites are linked to inflammation and gut barrier function, so they could become biomarkers or therapeutic targets for Crohn’s disease and ulcerative colitis. Patients may see future tests or...
This research links a gut bacterial metabolite to modulation of an immune receptor (GPR183) that is elevated in colon/rectum of ulcerative colitis patients, suggesting a possible microbiota‑to‑immune pathway relevant to...
Many people with Crohn’s disease or ulcerative colitis use biologic drugs; new clinical and real-world data about a subcutaneous infliximab option could affect treatment choice, switching decisions, and practical use in...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis and Pediatrics and family. The original article is from BMC Infectious Diseases.
Protein biomarkers that predict IBD years before diagnosis could enable earlier detection, inform risk-stratified monitoring, and reveal early disease pathways that might be targeted to prevent or delay onset.
This study identifies a new experimental compound (z18) that reduced inflammation in cell studies and mouse models of ulcerative colitis, suggesting a potential new avenue for IBD drug discovery.
The paper reports novel ibuprofen-derived compounds that reduce inflammation and restore intestinal immune balance in preclinical models of ulcerative colitis, suggesting a potential new drug-development direction that...
The paper suggests a specific molecule, MXRA7, links macrophage M1 polarization and epithelial pyroptosis—two processes implicated in ulcerative colitis tissue damage. If validated, this could point to new targets for...
The study points to a specific microbiome-derived micronutrient pathway (queuosine/queuine) that appears reduced in IBD, which could help explain part of microbiome-related changes in intestinal cells and suggest new...
Children diagnosed with IBD can develop other immune-related diseases, growth and weight problems, skin conditions, and serious infections over time. Knowing the frequency and risk factors helps families and clinicians...
Based on the title and source metadata, this appears to be a clinical trial phase 2 related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from New England...
If confirmed, an existing diabetes drug class (SGLT2 inhibitors) could offer an adjunct anti-inflammatory option for people with mild-to-moderate ulcerative colitis and might affect symptoms, biomarkers, and quality of...
This study reports a new engineered oral probiotic delivery system that may increase probiotic survival, target inflamed colon tissue, and change the gut microbiome in ways that reduced colitis in mice — a potential...
Physical activity is linked to general health and quality of life. If people with IBD—particularly those with more severe CD—are less active, tailored support could help improve wellbeing and manage disease-related...
Diarrhea is a common, burdensome symptom in IBD. This study suggests that inflammation-linked defects in enterocyte differentiation and reduced ion transporter expression may help explain persistent diarrhea and that...
This study links altered autophagy genes (ATG5, ATG16L1) in Crohn’s disease and ulcerative colitis with modulation by the gut bacterium Akkermansia muciniphila and its extracellular vesicles, suggesting a possible...
People with ulcerative colitis often face trial‑and‑error when starting advanced therapies. THAMES‑IBD aims to find biological and psychosocial markers that predict who will respond, which could eventually make treatment...
The study found higher recorded rates of hidradenitis suppurativa in people with Crohn’s disease and psoriatic arthritis, and a smaller increase in ulcerative colitis, suggesting clinicians should consider asking about...
The timing of depression versus GI diagnoses differs by condition: depression commonly comes before IBS but often follows Crohn’s disease. That matters because it suggests different gut–brain pathways and could change...
This registry study offers real-world data on ozanimod effectiveness, persistence, and safety in UC patients, which can help patients and clinicians set expectations beyond clinical trial settings.
This study follows people from diagnosis and shows that about half achieve clinically meaningful improvements in quality of life by 3 years, but many remain below general population norms.
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Infliximab. The original article is from Inflammatory Bowel Diseases.
Patients on biologic therapy often have drug levels and antidrug antibodies measured to guide care. This study suggests prior biologic history, disease type (UC vs CD) and which biologic is currently used may affect...
The analysis helps compare multiple advanced therapies when head‑to‑head trials are lacking, which may inform drug selection for induction and maintenance in moderate‑to‑severe UC, including for patients who have failed...
The paper suggests serum bilirubin levels statistically explain a meaningful fraction of the link between gut Enterobacterales abundance and endoscopic disease activity in UC, which may point to biologic pathways or...
This study points to possible differences in fiber intake and the food sources of tryptophan between IBD patients and healthy people—factors that could be relevant for future dietary guidance or research, but the results...
Decisions about when to build an ileal pouch after emergency colectomy matter to patients because timing could affect recovery, complications, and long-term pouch function. This study suggests timing within or after 6...
This large, long-term study suggests that having pets or farm animals during pregnancy or early childhood probably does not meaningfully change a child’s later risk of developing IBD, which may reassure families...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Digestive and liver...
MASLD was common in this IBD cohort and became more frequent as BMI increased; clinicians and patients may need to consider liver health when managing IBD, especially for people with overweight or obesity.
The study suggests that using infliximab as first-line therapy (rather than IV corticosteroids) may produce more durable remission and reduce long-term colectomy risk in moderate-to-severe ulcerative colitis.
RDW-CV, a routine blood-test parameter, may help signal higher inflammatory activity in ulcerative colitis and provide low-cost adjunctive information when assessing disease activity.
Based on the title and source metadata, this appears to be a case report related to Ulcerative colitis, Inflammatory bowel disease, and Pediatrics and family. The original article is from Archives of disease in...
Based on the title and source metadata, this appears to be a patient story related to Ulcerative colitis, Inflammatory bowel disease, and Tests and monitoring. The original article is from British medical journal.
Based on the title and source metadata, this appears to be a case report related to Ulcerative colitis, Inflammatory bowel disease, and Complications. The original article is from Cureus.
Based on the title and source metadata, this appears to be a patient education related to Ulcerative colitis, Inflammatory bowel disease, and Symptoms and flares. The original article is from California medicine.
Based on the title and source metadata, this appears to be a patient education related to Ulcerative colitis and Medications. The original article is from British medical journal (Clinical research ed.).
Based on the title and source metadata, this appears to be a patient education related to Ulcerative colitis, Inflammatory bowel disease, and Medications. The original article is from British medical journal (Clinical...
Based on the title and source metadata, this appears to be a case report related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from British medical journal...
IBD affects more than the digestive tract and long-term care now emphasizes controlling inflammation and monitoring (including endoscopic healing) to lower complication risk and improve quality of life.
